286 related articles for article (PubMed ID: 8882074)
1. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease.
Grove A; Lipworth BJ; Reid P; Smith RP; Ramage L; Ingram CG; Jenkins RJ; Winter JH; Dhillon DP
Thorax; 1996 Jul; 51(7):689-93. PubMed ID: 8882074
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Ulrik CS
Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
[TBL] [Abstract][Full Text] [Related]
3. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol.
Blake K; Pearlman DS; Scott C; Wang Y; Stahl E; Arledge T
Ann Allergy Asthma Immunol; 1999 Feb; 82(2):205-11. PubMed ID: 10071526
[TBL] [Abstract][Full Text] [Related]
4. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
5. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
6. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
7. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
Cazzola M; Vinciguerra A; Di Perna F; Matera MG
Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
[TBL] [Abstract][Full Text] [Related]
8. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
9. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
10. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
[TBL] [Abstract][Full Text] [Related]
12. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD.
Man WD; Mustfa N; Nikoletou D; Kaul S; Hart N; Rafferty GF; Donaldson N; Polkey MI; Moxham J
Thorax; 2004 Jun; 59(6):471-6. PubMed ID: 15170026
[TBL] [Abstract][Full Text] [Related]
13. The functional impact of adding salmeterol and tiotropium in patients with stable COPD.
Cazzola M; Centanni S; Santus P; Verga M; Mondoni M; di Marco F; Matera MG
Respir Med; 2004 Dec; 98(12):1214-21. PubMed ID: 15588043
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
[TBL] [Abstract][Full Text] [Related]
15. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
16. Overnight protection by inhaled salmeterol on exercise-induced asthma in children.
Carlsen KH; Røksund O; Olsholt K; Njå F; Leegaard J; Bratten G
Eur Respir J; 1995 Nov; 8(11):1852-5. PubMed ID: 8620951
[TBL] [Abstract][Full Text] [Related]
17. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Voduc N; Fitzpatrick M; Webb KA
Eur Respir J; 2004 Jul; 24(1):86-94. PubMed ID: 15293609
[TBL] [Abstract][Full Text] [Related]
18. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.
Cazzola M; Calderaro F; Califano C; Di Pema F; Vinciguerra A; Donner CF; Matera MG
Eur J Clin Pharmacol; 1999 Jan; 54(11):829-33. PubMed ID: 10027655
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
[TBL] [Abstract][Full Text] [Related]
20. Prevention of exercise induced asthma by inhaled salmeterol xinafoate.
Green CP; Price JF
Arch Dis Child; 1992 Aug; 67(8):1014-7. PubMed ID: 1355645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
